223 related articles for article (PubMed ID: 20824463)
21. Rare diseases and orphan drugs.
Taruscio D; Capozzoli F; Frank C
Ann Ist Super Sanita; 2011; 47(1):83-93. PubMed ID: 21430345
[TBL] [Abstract][Full Text] [Related]
22. Intractable and rare diseases research in Asia.
Song P; Gao J; Inagaki Y; Kokudo N; Tang W
Biosci Trends; 2012 Apr; 6(2):48-51. PubMed ID: 22621985
[TBL] [Abstract][Full Text] [Related]
23. The Orphan Drug Act. The first 7 years.
Asbury CH
JAMA; 1991 Feb; 265(7):893-7. PubMed ID: 1992188
[TBL] [Abstract][Full Text] [Related]
24. A regulatory overview about rare diseases.
Llinares J
Adv Exp Med Biol; 2010; 686():193-207. PubMed ID: 20824447
[TBL] [Abstract][Full Text] [Related]
25. National Organization for Rare Disorders (NORD): providing advocacy for people with rare disorders.
Putkowski S
NASN Sch Nurse; 2010 Jan; 25(1):38-41. PubMed ID: 20440954
[No Abstract] [Full Text] [Related]
26. The Orphan Drug Act and the development of stem cell-based products for rare diseases.
Freeman SN; Burke KA; Imoisili MA; Coté TR
Cell Stem Cell; 2010 Sep; 7(3):283-7. PubMed ID: 20804965
[TBL] [Abstract][Full Text] [Related]
27. Orphan drugs: the regulatory environment.
Franco P
Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
[TBL] [Abstract][Full Text] [Related]
28. Adopting orphan drugs--two dozen years of treating rare diseases.
Haffner ME
N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
[No Abstract] [Full Text] [Related]
29. Rare opportunities appear on the horizon to treat rare diseases.
Torres C
Nat Med; 2010 Mar; 16(3):241. PubMed ID: 20208483
[No Abstract] [Full Text] [Related]
30. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
31. Orphan drug development in the United States.
Groft SC
CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
[TBL] [Abstract][Full Text] [Related]
32. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
Arno PS; Bonuck K; Davis M
Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
[TBL] [Abstract][Full Text] [Related]
33. [Orphan diseases and orphan medicines: a Belgian and European study].
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
[TBL] [Abstract][Full Text] [Related]
34. The role of academic institutions in the development of drugs for rare and neglected diseases.
Coles LD; Cloyd JC
Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
[TBL] [Abstract][Full Text] [Related]
35. Developing interactions with industry in rare diseases: lessons learned and continuing challenges.
Berry SA; Coughlin CR; McCandless S; McCarter R; Seminara J; Yudkoff M; LeMons C
Genet Med; 2020 Jan; 22(1):219-226. PubMed ID: 31337884
[TBL] [Abstract][Full Text] [Related]
36. The Minor Use and Minor Species Animal Health Act: past, present, and future.
Haley CJ
Food Drug Law J; 2006; 61(1):13-43. PubMed ID: 16838456
[No Abstract] [Full Text] [Related]
37. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
38. Legal and regulatory aspects of orphan drugs.
Shani S; Yahalom Z
Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():110-5. PubMed ID: 24380129
[TBL] [Abstract][Full Text] [Related]
39. Orphanage at the FDA.
Chen E
J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
[No Abstract] [Full Text] [Related]
40. Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience.
Lomash RM; Shchelochkov O; Chandler RJ; Venditti CP; Pariser AR; Ottinger EA;
Hum Gene Ther; 2023 Mar; 34(5-6):217-227. PubMed ID: 36694456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
